Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2006-07-04
2006-07-04
O'Hara, Eileen B. (Department: 1646)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S192100, C514S012200, C530S350000, C536S023400, C536S023500
Reexamination Certificate
active
07070783
ABSTRACT:
The present invention relates to a receptor molecule which binds to TNF comprising all or a functional portion of the extracellular domain (ECD) of two or more TNF-Rs linked via one or more polypeptide linkers. The receptor can further comprise a signal peptide of a secreted protein, such as the signal peptide of the extracellular domain of the TNF-R or the signal peptide of a cytokine. The invention also relates to isolated DNA encoding a receptor molecule which binds to TNF, comprising two or more sequences encoding all or a functional portion of the ECD of TNF-Rs linked via one or more sequences encoding a polypeptide linker. The invention further relates to a method of making a construct which expresses all or a functional portion of the ECD of two or more TNF-Rs linked via one or more polypeptide linkers and cells which express the construct. The invention also relates to a method of inhibiting the biological activity of TNF in a host comprising administering to the host an effective amount of a receptor molecule of the present invention. The invention further relates to receptor molecules which bind cytokines that bind to receptor molecules comprising more than one subunit.
REFERENCES:
patent: 5395760 (1995-03-01), Smith et al.
patent: 5447851 (1995-09-01), Beutler et al.
patent: 5470952 (1995-11-01), Stahl et al.
patent: 5478925 (1995-12-01), Wallach et al.
patent: 5610279 (1997-03-01), Brockhaus et al.
patent: 5721121 (1998-02-01), Etcheverry et al.
patent: 5736387 (1998-04-01), Paul et al.
patent: 5945397 (1999-08-01), Smith et al.
patent: 5958409 (1999-09-01), Turk et al.
patent: 6015557 (2000-01-01), Tobinick et al.
patent: RE36755 (2000-06-01), Smith et al.
patent: 526 905 (1993-02-01), None
patent: WO 92/07076 (1992-04-01), None
patent: WO 95 03827 (1995-02-01), None
patent: WO 98/05357 (1998-02-01), None
patent: WO 00/59530 (2000-10-01), None
Lesslauer, W., et al., “Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality”,Eur. J. Immunol,21:2883-2886 (1991).
Baker, D., et al., “Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins”,Eur. J. Immunol.,24:2040-2048 (1994).
Corocoran, A.E., et al., “Characterization of ligand binding by the human p55 tumour-necrosis-factor receptor”,Eur. J. Biochem.,223:831-840 (1994).
Kim, C.-D. and Bloedow, D.C., “Administration Route Dependency of Distribution of PEGylated Recombinant HumanTumor Necrosis Factor Binding Protein (rhTNFbp-PEG20K dimer) Following i.v. and s.c. Injection in Rats”,Arch. Pharm. Res.,17(5) :381-382 (1994).
Kolls, J. et at., “Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer”,Proc. Natl. Acad. Sci. USA,91:215-219 (1994).
Elliott, M.J., et al., “Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α”,Arthritis&Rheumatism,36(12)1681-1690 (1993).
Butler, D.M., et al., “TNF receptor fusion proteins are effective inhibitors of TNF-mediated cytotoxicity on human KYM-1D4 rhabdomyosarcoma cells”,Cytokine,6(6) :616-623 (1994).
Bemelmans, M.H.A., et al., “Tissue distribution and clearance of soluble murine TNF receptors in mice”,Cytokine,6(6) :608-615 (1994).
Neve, R., et al., “Expression of an Efficient Small Molecular Weight Tumour Necrosis Factor/Lymphotoxin Antagonist,”Cytokine 8(5) : 365-370 (May 1996).
Chernajovsky Yuti
Feldmann Marc
Neve Richard
Cooper & Dunham LLP
O'Hara Eileen B.
The Mathilda and Terence Kennedy Institute of Rheumatology
White, Esq. John P.
LandOfFree
Small molecular weight TNF receptor multimeric molecule does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Small molecular weight TNF receptor multimeric molecule, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Small molecular weight TNF receptor multimeric molecule will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3605251